Q32 BIO TO REPORT 36-WEEK TOPLINE RESULTS FROM PART B OF SIGNAL-AA CLINICAL TRIAL OF BEMPIKIBART IN ALOPECIA AREATA ON JULY 13, 2026

Reuters · 1d ago

Please log in to view news